| Mark Jeffrey Burstein, MD | |
|
400 Middletown Blvd, Suite 100, Langhorne, PA 19047-1819 | |
| (215) 757-7300 | |
| (215) 750-7111 |
| Full Name | Mark Jeffrey Burstein |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 21 Years |
| Location | 400 Middletown Blvd, Langhorne, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972788214 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD433358 (Pennsylvania) | Primary |
| 207Y00000X | Otolaryngology | 25MA08362800 (New Jersey) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary Medical Center | Langhorne, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ent And Facial Plastic Surgical Associates, Llp | 0143294074 | 8 |
| Ent And Facial Plastic Surgical Associates, Llp | 0143294074 | 8 |
News Archive
Not surprisingly, the plan has drawn complaints from the left about cuts to Social Security and Medicare, and from the right about defense cuts and tax increases. But the senators are right about the need to simplify and broaden the tax code and to put entitlements on a sustainable footing without slashing aid to the most vulnerable.
A survey of restaurant and food establishment personnel reveals that for food-allergic consumers, dining out may be a greater risk than they realize.
Cordis Corporation today announced that a U.S. District Court jury in Wilmington, Delaware found that Boston Scientific's Taxus drug-eluting stent and its Liberte and Express bare metal stents infringe Cordis' pioneering Palmaz patent for balloon expandable stents
Pharmaceutical giant Pfizer has adapted the label of its Celebrex arthritis drug and added a prominent warning of possible cardiovascular risks, such as increased risk of heart attacks.
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.
› Verified 3 days ago
| Entity Name | Ent & Facial Plastic Surgical Associates, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144215807 PECOS PAC ID: 0143294074 Enrollment ID: O20040825000606 |
News Archive
Not surprisingly, the plan has drawn complaints from the left about cuts to Social Security and Medicare, and from the right about defense cuts and tax increases. But the senators are right about the need to simplify and broaden the tax code and to put entitlements on a sustainable footing without slashing aid to the most vulnerable.
A survey of restaurant and food establishment personnel reveals that for food-allergic consumers, dining out may be a greater risk than they realize.
Cordis Corporation today announced that a U.S. District Court jury in Wilmington, Delaware found that Boston Scientific's Taxus drug-eluting stent and its Liberte and Express bare metal stents infringe Cordis' pioneering Palmaz patent for balloon expandable stents
Pharmaceutical giant Pfizer has adapted the label of its Celebrex arthritis drug and added a prominent warning of possible cardiovascular risks, such as increased risk of heart attacks.
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Jeffrey Burstein, MD 400 Middletown Blvd, Suite 100, Langhorne, PA 19047-1819 Ph: (215) 757-7300 | Mark Jeffrey Burstein, MD 400 Middletown Blvd, Suite 100, Langhorne, PA 19047-1819 Ph: (215) 757-7300 |
News Archive
Not surprisingly, the plan has drawn complaints from the left about cuts to Social Security and Medicare, and from the right about defense cuts and tax increases. But the senators are right about the need to simplify and broaden the tax code and to put entitlements on a sustainable footing without slashing aid to the most vulnerable.
A survey of restaurant and food establishment personnel reveals that for food-allergic consumers, dining out may be a greater risk than they realize.
Cordis Corporation today announced that a U.S. District Court jury in Wilmington, Delaware found that Boston Scientific's Taxus drug-eluting stent and its Liberte and Express bare metal stents infringe Cordis' pioneering Palmaz patent for balloon expandable stents
Pharmaceutical giant Pfizer has adapted the label of its Celebrex arthritis drug and added a prominent warning of possible cardiovascular risks, such as increased risk of heart attacks.
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.
› Verified 3 days ago
Lee H. Miller, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 400 Middletown Blvd, Suite 100, Langhorne, PA 19047 Phone: 215-757-7300 Fax: 215-750-7111 | |
Jeffrey M. Briglia, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3 Cornerstone Dr Ste 703, Langhorne, PA 19047 Phone: 267-689-1000 | |
Brett L. Moses, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 400 Middletown Blvd, Suite 100, Langhorne, PA 19047 Phone: 973-757-7300 Fax: 973-750-7111 | |
Jonathan Mallen, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 400 Middletown Blvd Ste 100, Langhorne, PA 19047 Phone: 215-757-7300 | |
Dr. Michael Ondik, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 402 Middletown Blvd, Suite 210, Langhorne, PA 19047 Phone: 215-752-4020 | |
Dr. Judith E Gallagher-braun, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3 Cornerstone Dr Ste 703, Langhorne, PA 19047 Phone: 267-689-1000 | |
Dr. John Timothy Gallagher, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1205 Langhorne Newtown Rd, Suite102, Langhorne, PA 19047 Phone: 215-757-3635 Fax: 215-757-3999 |